Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of v...
Gespeichert in:
Veröffentlicht in: | Human vaccines & immunotherapeutics 2021-09, Vol.17 (9), p.2863-2867 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2867 |
---|---|
container_issue | 9 |
container_start_page | 2863 |
container_title | Human vaccines & immunotherapeutics |
container_volume | 17 |
creator | Wang, Guangfei Zhu, Lin Zhu, Yiqing Ye, Qiaofeng Yu, Xin Fu, Meng Lu, Jinmiao Li, Xiaoxia Huang, Yidie Zhang, Junqi Lan, Jianger Li, Ziwei Zhai, Xiaowen Xu, Hong Li, Zhiping |
description | This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service. |
doi_str_mv | 10.1080/21645515.2021.1913964 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2021_1913964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_76c4bd82362d49f1b7881436fe12f78b</doaj_id><sourcerecordid>2518226960</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</originalsourceid><addsrcrecordid>eNp9kUuP0zAURiMEYkbD_ASQl2xScv2Ks0GgDo9KI82Ch5BYWI5z3XqUxMVOi_LvcWmnYjZ4Y-v63O_aOkXxEqoFVKp6Q0FyIUAsaEVhAQ2wRvInxeWhXgrBfzw9n0FcFNcp3Vd51RXlUj4vLhhTSnKAy-LnF-NwmknaxT3OpJ2J7f3orenJdmPiYKxPUyJhJMu776ubEhqyN9b60Uw-F10MAzEk-XHdI7E4ThiJz_AmEy-KZ870Ca9P-1Xx7eOHr8vP5e3dp9Xy_W1pBeNT2WHDWi4c1NAxVzW1kyhbAaga4BYdMtai4kww4ZRtsLNCGoHIJVraipZdFatjbhfMvd5GP5g462C8_lsIca1NnLztUdfS8rZTlEna8cZBWysFnEmHQF2tDllvj1nbXTvkUflH0fSPQh_fjH6j12GvFVOgKOSA16eAGH7tME168Mli35sRwy5pKjJGZSOrjIojamNIKaI7j4FKHzzrB8_64FmfPOe-V_--8dz1YDUD746AH13IDn-H2Hd6MnMfootmzE41-_-MPz5mt3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2518226960</pqid></control><display><type>article</type><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><source>MEDLINE</source><source>PubMed (Medline)</source><source>Alma/SFX Local Collection</source><creator>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</creator><creatorcontrib>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</creatorcontrib><description>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2021.1913964</identifier><identifier>PMID: 33886411</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Child ; China - epidemiology ; clinical pharmacists ; COVID-19 ; COVID-19 Vaccines ; Humans ; Pharmacists ; Research Paper ; safety ; SARS-CoV-2 ; Vaccination ; vaccine</subject><ispartof>Human vaccines & immunotherapeutics, 2021-09, Vol.17 (9), p.2863-2867</ispartof><rights>2021 Taylor & Francis Group, LLC 2021</rights><rights>2021 Taylor & Francis Group, LLC 2021 Taylor & Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</citedby><cites>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</cites><orcidid>0000-0001-6194-023X ; 0000-0001-5132-9197 ; 0000-0001-5310-5306</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381821/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381821/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33886411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Guangfei</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Zhu, Yiqing</creatorcontrib><creatorcontrib>Ye, Qiaofeng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Fu, Meng</creatorcontrib><creatorcontrib>Lu, Jinmiao</creatorcontrib><creatorcontrib>Li, Xiaoxia</creatorcontrib><creatorcontrib>Huang, Yidie</creatorcontrib><creatorcontrib>Zhang, Junqi</creatorcontrib><creatorcontrib>Lan, Jianger</creatorcontrib><creatorcontrib>Li, Ziwei</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</description><subject>Child</subject><subject>China - epidemiology</subject><subject>clinical pharmacists</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Pharmacists</subject><subject>Research Paper</subject><subject>safety</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>vaccine</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUuP0zAURiMEYkbD_ASQl2xScv2Ks0GgDo9KI82Ch5BYWI5z3XqUxMVOi_LvcWmnYjZ4Y-v63O_aOkXxEqoFVKp6Q0FyIUAsaEVhAQ2wRvInxeWhXgrBfzw9n0FcFNcp3Vd51RXlUj4vLhhTSnKAy-LnF-NwmknaxT3OpJ2J7f3orenJdmPiYKxPUyJhJMu776ubEhqyN9b60Uw-F10MAzEk-XHdI7E4ThiJz_AmEy-KZ870Ca9P-1Xx7eOHr8vP5e3dp9Xy_W1pBeNT2WHDWi4c1NAxVzW1kyhbAaga4BYdMtai4kww4ZRtsLNCGoHIJVraipZdFatjbhfMvd5GP5g462C8_lsIca1NnLztUdfS8rZTlEna8cZBWysFnEmHQF2tDllvj1nbXTvkUflH0fSPQh_fjH6j12GvFVOgKOSA16eAGH7tME168Mli35sRwy5pKjJGZSOrjIojamNIKaI7j4FKHzzrB8_64FmfPOe-V_--8dz1YDUD746AH13IDn-H2Hd6MnMfootmzE41-_-MPz5mt3A</recordid><startdate>20210902</startdate><enddate>20210902</enddate><creator>Wang, Guangfei</creator><creator>Zhu, Lin</creator><creator>Zhu, Yiqing</creator><creator>Ye, Qiaofeng</creator><creator>Yu, Xin</creator><creator>Fu, Meng</creator><creator>Lu, Jinmiao</creator><creator>Li, Xiaoxia</creator><creator>Huang, Yidie</creator><creator>Zhang, Junqi</creator><creator>Lan, Jianger</creator><creator>Li, Ziwei</creator><creator>Zhai, Xiaowen</creator><creator>Xu, Hong</creator><creator>Li, Zhiping</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6194-023X</orcidid><orcidid>https://orcid.org/0000-0001-5132-9197</orcidid><orcidid>https://orcid.org/0000-0001-5310-5306</orcidid></search><sort><creationdate>20210902</creationdate><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><author>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Child</topic><topic>China - epidemiology</topic><topic>clinical pharmacists</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Pharmacists</topic><topic>Research Paper</topic><topic>safety</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Guangfei</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Zhu, Yiqing</creatorcontrib><creatorcontrib>Ye, Qiaofeng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Fu, Meng</creatorcontrib><creatorcontrib>Lu, Jinmiao</creatorcontrib><creatorcontrib>Li, Xiaoxia</creatorcontrib><creatorcontrib>Huang, Yidie</creatorcontrib><creatorcontrib>Zhang, Junqi</creatorcontrib><creatorcontrib>Lan, Jianger</creatorcontrib><creatorcontrib>Li, Ziwei</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Guangfei</au><au>Zhu, Lin</au><au>Zhu, Yiqing</au><au>Ye, Qiaofeng</au><au>Yu, Xin</au><au>Fu, Meng</au><au>Lu, Jinmiao</au><au>Li, Xiaoxia</au><au>Huang, Yidie</au><au>Zhang, Junqi</au><au>Lan, Jianger</au><au>Li, Ziwei</au><au>Zhai, Xiaowen</au><au>Xu, Hong</au><au>Li, Zhiping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2021-09-02</date><risdate>2021</risdate><volume>17</volume><issue>9</issue><spage>2863</spage><epage>2867</epage><pages>2863-2867</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>33886411</pmid><doi>10.1080/21645515.2021.1913964</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6194-023X</orcidid><orcidid>https://orcid.org/0000-0001-5132-9197</orcidid><orcidid>https://orcid.org/0000-0001-5310-5306</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2164-5515 |
ispartof | Human vaccines & immunotherapeutics, 2021-09, Vol.17 (9), p.2863-2867 |
issn | 2164-5515 2164-554X |
language | eng |
recordid | cdi_crossref_primary_10_1080_21645515_2021_1913964 |
source | MEDLINE; PubMed (Medline); Alma/SFX Local Collection |
subjects | Child China - epidemiology clinical pharmacists COVID-19 COVID-19 Vaccines Humans Pharmacists Research Paper safety SARS-CoV-2 Vaccination vaccine |
title | Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A18%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20survey%20by%20clinical%20pharmacists%20on%20COVID-19%20vaccination%20from%20a%20single%20center%20in%20China&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Wang,%20Guangfei&rft.date=2021-09-02&rft.volume=17&rft.issue=9&rft.spage=2863&rft.epage=2867&rft.pages=2863-2867&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2021.1913964&rft_dat=%3Cproquest_cross%3E2518226960%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2518226960&rft_id=info:pmid/33886411&rft_doaj_id=oai_doaj_org_article_76c4bd82362d49f1b7881436fe12f78b&rfr_iscdi=true |